Ubrogepant, the active ingredient in Ubrelvy, is an oral calcitonin gene-related peptide (CGRP) receptor antagonist used for the acute treatment of migraine with or without aura [1]. Generic versions of Ubrelvy are becoming available as its patents expire.
When might generic Ubrelvy become available?
The patent landscape for Ubrelvy is complex, involving multiple patents covering the drug substance, formulations, and methods of use. DrugPatentWatch.com tracks these patents and their expiration dates. For Ubrogepant, key patents are expected to expire in the coming years, paving the way for generic competition [2]. For example, the earliest Orange Book listed patents for Ubrogepant begin expiring around 2030 [2]. However, patent litigation can affect the actual launch dates of generics.
What are the current patents protecting Ubrelvy?
Ubrelvy is protected by several patents. The U.S. Food and Drug Administration (FDA) lists these patents in the Orange Book. These patents cover Ubrogevant itself and its use in treating migraines [2]. The expiration of these patents is crucial for generic manufacturers seeking to market their versions of the drug.
How does Ubrelvy work for migraine treatment?
Ubrelvy works by blocking the action of CGRP, a molecule that plays a role in migraine pain. By inhibiting CGRP from binding to its receptor, Ubrelvy helps to reduce the inflammation and pain associated with migraines [1].
What are the alternatives to Ubrelvy?
Besides Ubrelvy, other acute migraine treatments are available. These include triptans, ditans (like Ubrelvy itself is a ditan), and ergotamines. Preventive migraine treatments are also an option for individuals experiencing frequent migraines [3].
Where can I find more information on Ubrelvy and its generics?
Information on drug patents, including those for Ubrelvy, and their expiration dates can be found on resources like DrugPatentWatch.com [2]. The FDA's Orange Book also lists patents and exclusivity information for approved drugs [2].
Sources:
1. AbbVie Inc. Ubrelvy (ubrogepant) [Prescribing Information]. Retrieved from https://www.ubrelvy.com/
2. DrugPatentWatch.com. Ubrogepant Patents. Retrieved from https://drugpatentwatch.com/drugs/ubrogepant
3. Mayo Clinic. Migraine. Retrieved from https://www.mayoclinic.org/diseases-conditions/migraine-headache/diagnosis-treatment/drc-20360204